Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kymera Therapeutics Inc (Kymera) is a clinical-stage biotechnology company that develops innovative medicines to treat human diseases. It carries out advancing targeted protein degradation technologies to address disease-causing proteins. The company's pipeline includes KT-621 for treating atopic dermatitis, asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, bullous pemphigoid and others. Kymera's other pipeline includes KT-579 targeting lupus, sjogrens, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, diabetes mellitus and others; KT-474 for hidradenitis suppurativa and atopic dermatitis; KT-295 treats autoimmune and inflammatory diseases. The company operates across the US. Kymera is headquartered in Watertown, Massachusetts, the US.
Headquarters
United States of America
Address
500 North Beacon Street, 4th Floor, Watertown, Massachusetts, 02472
Website
www.kymeratx.com
Telephone
1 857 2855300
No of Employees
238
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KYMR (NASD)
Revenue (2024)
$39.2M
-16.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-39.1%
(2024 vs 2023)
Market Cap*
$8.8B
Net Profit Margin (2024)
XYZ
-67.0%
(2024 vs 2023)
* As of and is in US$
Kymera Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| KT-621: |
| Atopic Dermatitis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In June, the company partnered with Gilead Sciences to develop a novel molecular glue degrader targeting CDK2 for oncology treatments, including breast cancer. |
| 2024 | Plans/Strategy | In July, the company announced its plans to expand the ongoing Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD) Phase 2 trials to more rapidly progress toward pivotal studies. |
| 2024 | Contracts/Agreements | In May, the company entered into a partnership with NEOsphere Biotechnologies to identify new molecular glue targets. |
Competitor Comparison
| Key Parameters | Kymera Therapeutics Inc | Arvinas Inc | Nurix Therapeutics Inc | C4 Therapeutics Inc | Foghorn Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Watertown | New Haven | Brisbane | Watertown | Cambridge |
| State/Province | Massachusetts | Connecticut | California | Massachusetts | Massachusetts |
| No. of Employees | 238 | 246 | 317 | 104 | 106 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Felix J. Baker, Ph.D. | Chairman | Executive Board | 2026 | 57 |
| Nello Mainolfi, Ph.D | Director; Chief Executive Officer; President | Executive Board | 2019 | 47 |
| Terence Rooney | Chief Medical Officer | Senior Management | 2026 | - |
| Elizabeth Laws, PhD | Head - KT-621 Development Program; Senior Vice President | Senior Management | 2026 | - |
| John Maraganore, PhD | Director | Non Executive Board | 2022 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer